1 |
B.P. Imbimbo, S. Daniotti, A. Vidi, D. Foschi, F. Saporiti and L. Ferrante, Discontinuous oral absorption of cimetro-pium bromide, A new antispasmodic drug, J. Pharm. Sci., 75(7), 680-684 (1986)
DOI
|
2 |
식품의약품안전청 고시 제 2001-57호, 생물학적 동등성 시험기준 (2001. 9. 5)
|
3 |
M. Kajbaf, M. Jahanshahi, K. Pattichis, J.W. Gorrod and S. Naylor, Rapid and efficient purification of cimetropium bromide and mifentidine drug metabolite mixtures derived from microsomal incubates for analysis by mass spectrometry, J. Chromatogr., 575, 75-85 (1992)
DOI
ScienceOn
|
4 |
이영주, 최정호, 송세흠, 서철환, 김동섭, 박인숙, 최기환, 나한광, 정석재, 이민화, 심창구. K-BEtest, 새로운 생물학적 동등성 시험 통계처리 프로그램의 개발, 약제학회지, 28, 223-229 (1998)
|
5 |
Statistical Solutions Ltd., Equiv. Test_ 1.0, U.K. (1998)
|
6 |
Food and Drug Administration (FDA): Guidance for Industry; Waiver of in vivo bioavailability and bioequivalence study for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, Center for Drug Evaluation and Research (CDER), August, (2000)
|
7 |
C. Scarpignato, A. Donetti and B.P. Imbimbo, Cimetropium bromide: A new antimuscarinic compound endowed with antispasmodic activity, Drugs of today, 24(12), 859-876 (1988)
|
8 |
식품의약품안전청 고시 제 1998-86호, 생물학적 동등성 시험기준 (1998. 8. 26)
|
9 |
C. Scarpignato and G. Bianchi-Porro, Cimetropium bromide: A new antispasmodic compound: pharmacology and thera-peutic perspectives, Int. J. Clin. Pharm. Res., 6, 467-477 (1985)
|